Since elevated PD-L1 levels are closely linked to enhanced immune evasion by tumors, targeting the PD-1/PD-L1 axis may represent a promising treatment strategy for individuals with lung cancer who also suffer from OSA. This evidence concerns the gene PDCD1 and obstructive sleep apnea syndrome.